Opioid-Induced Respiratory Depression on Postoperative Day One
Mr. K, 58, is postoperative day 1 after open reduction and internal fixation of a femur fracture. He has a hydromorphone PCA: 0.2 mg demand, 8-minute lockout, 0.2 mg/hr basal. Home medications include extended-release morphine 30 mg BID and gabapentin 600 mg TID; he also received lorazepam 1 mg for sleep at 2200. At 0230 the RN finds him snoring loudly and minimally responsive to a sternal rub. RR 6/min and shallow, SpO2 86% on 2 L, pinpoint pupils, pain 0 when aroused. BP 108/62, HR 58. A colleague says, "Just push the whole 0.4 mg of naloxone and get it over with."
1. What is your assessment and what are your immediate priorities in order?
Read the worked answer
Assessment: opioid-induced respiratory depression with oversedation (POSS 3–4) and hypoxemia, compounded by a basal opioid infusion, a benzodiazepine, gabapentin, and likely obstructive sleep apnea (loud snoring). Pinpoint pupils and RR 6 confirm the opioid effect.
Immediate priorities, in order:
- Call for help; stay with the patient.
- Stop the PCA and the basal infusion.
- Open the airway (head-tilt/chin-lift or jaw thrust), stimulate, and give oxygen.
- Ventilate with a bag-valve-mask if respiratory effort is inadequate - oxygenation and ventilation come first, and naloxone does not correct hypoxia instantly.
- Continuous SpO2, ECG, BP; capnography if available.
- Then titrated naloxone.
Do not push 0.4 mg. In an opioid-tolerant patient, full reversal precipitates acute withdrawal, severe pain, a catecholamine surge, pulmonary edema, and seizures. The goal is adequate ventilation, not a wide-awake patient.
2. How do you dose the naloxone, what do you expect, and what monitoring does the pharmacology require?
Read the worked answer
Titrated reversal:
- Dilute 0.4 mg in 10 mL 0.9% NaCl (0.04 mg/mL).
- Give 0.04–0.08 mg IV every 2 minutes, titrated to RR ≥ 8–10/min, SpO2 ≥ 92%, and the ability to respond - not full wakefulness.
- Repeat as needed, ventilating between doses.
- If there is no response after 2–3 doses, reconsider the cause: hypoglycemia, stroke, head injury, other sedatives. Naloxone does nothing for benzodiazepine or gabapentin effect.
Monitoring: naloxone's half-life (roughly 30–90 minutes) is shorter than hydromorphone's, so re-sedation is expected. Observe at least 2–4 hours after the last dose, consider a low-dose infusion if repeated boluses are required, and continue continuous respiratory monitoring with frequent sedation scoring.
Then: once he is alert, reassess pain, restart the PCA without a basal (or at a much lower rate) only after discussion with the surgeon or acute pain service, and re-evaluate concurrent sedatives.
3. What system and education changes would reduce the chance of a repeat event?
Read the worked answer
- Question basal infusions in patients with OSA risk, obesity, or concurrent sedatives; many PCAs do not need one, and the basal rate was a major contributor here.
- Screen and document OSA risk; add capnography or scheduled sedation scoring (POSS) to the monitoring standard rather than relying on spot-check SpO2.
- Avoid concurrent benzodiazepines with opioids; keep multimodal analgesia (gabapentin is appropriate, but review timing and dose).
- Educate the patient and family: "If you cannot wake him easily, call us immediately" - and make sure the call bell is within reach.
- Debrief the team and file a quality report; consider a unit initiative on opioid safety rather than a single nurse being blamed. Document the assessments, interventions, and response.
Recall alone would not have prevented this: the key judgment was recognizing that the combination of a basal opioid, a benzodiazepine, gabapentin, and probable OSA created risk well before the event.